Consumers’ perception of sleep aids: OTCs, natural products, and devices

After significant gains in recent past, sales of OTC sleeping aids slow, but alternatives show promise

Findings from our upcoming Nonprescription Drugs USA study estimate that sales of OTC sleeping aids post 3.4% growth to reach $244 million at the factory level in 2016.

After seeing significant growth rates ranging from 50.0% to 15.0% per year in the recent past, the market for OTC sleeping aids is still growing, but at a much slower pace. ZzzQuil (Procter & Gamble), Unisom (Sanofi), and private-label sleeping aids posted growth while the rest of the market was flat or declining in 2016. Continue reading

Nonprescription Drugs USA

Top Three Drivers of the U.S. OTC Market

Estimated at over $24 billion at the manufacturers’ level in 2014, the U.S. nonprescription drugs market shows interesting opportunities for its players, posting growth in five out of the seven product classes tracked in Kline’s annual Nonprescription Drugs USA report. Let’s take a look at the top three drivers behind this market’s success:

  1. Rx-to-OTC switches – the big game changer

Rx-to-OTC switches represent the core driver of market growth as they involve large, popular brands, bringing former prescription users to the OTC market. According to our recently released Rx-to-OTC Switch Pipelines USA: Competitive Assessment, the increasingly favorable regulatory environment facilitated the approval of four new and important switches, in categories that five years ago would have been considered as challenging.Continue reading